A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis
Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR, Mandalia S, Bower M, Gazzard B, Nelson M
J Clin Gastroenterol. 2009 Sep 9.

A multicentre cohort experience with double-boosted protease inhibitors.
Stebbing J, Scourfield A, Koh G, Taylor C, Taylor S, Wilkins E, Gazzard B, Nelson M, Jones R.
J Antimicrob Chemother. 2009 Aug;64(2):434-5.

A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
Fisher M,  Moyle GJ, Shahmanesh  M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G for the SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK
Journal of Acquired Immune Deficiency Syndromes. 2009:51:562-568

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN
J Infect Dis. 2009 Sep 15;200(6):973-83.

Acute hepatitis C is not associated with abnormal fibroscan readings
Holmes P, Low E, Bower M, Anderson M & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 30

Advances in sexually transmitted infections of the gastrointestinal tract
Ng SC, Gazzard B.
Nat Rev Gastroenterol Hepatol. 2009 Aug 25

AIDS Kaposi’s sarcoma: outcomes in 254 consecutive patients diagnosed in modern times
Powles S, Weir J, Francis N, Newsom-Davis T, Crook T, Boffito M, Nelson M & Bower M.
HIV Medicine 2009, 10 (Suppl1), 10.

Antiretroviral rounds. Too many options?
Walmsley S, Wilkin T, Moyle G
AIDS Clin Care. 2009;21:13-5.

Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting
Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P
AIDS Read. 2009;19:22-31.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.
Br J Nutr. 2009 Jun 1:1-9

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.
Br J Nutr. 2009 Jun 1:1-9.

Catscratch disease: a diagnostic conundrum
Scott C, Azwa A, Cohen C, McIntyre M, Desmond N
Int J STD AIDS. 2009 Aug; 20(8) 585-6

CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA
Haematologica. 2009 Jun;94(6):875-80

Clinical experience of raltegravir in salvage patients failing therapy, 48-week data
Teague A, Scott C, Bower M, Gazzard B & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 17

Clinical experience with maraviroc (UK 427857 or Celsentri) with an optimised background regimen in highly treatment-experienced patients.
Teague A, Underwood J, Scott C, Bower M, Gazzard B & Nelson M
HIV Medicine 2009, 10 (Suppl1), 18.

Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials
Moyle G, Rajicic N, Goodrich J, Mayer H, Valdez H.
AIDS 2009: 23:1613.

Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
Bower M, Veraitch O, Szydlo R, Charles P, Kelleher P, Gazzard B, Nelson M, Stebbing J.
Blood. 2009 May 7;113(19):4521-4.

Darunavir/ritonavir once daily: a single-centre cohort experience
. Scott C, Teague A, Bower M, Gazzard B & Nelson M
HIV Medicine 2009, 10 (Suppl1), 8

Drug-drug interactions involving new antiretroviral drugs and drug classes.
Soodalter J, Sousa M, Boffito M
Curr Opin Infect Dis. 2009 Feb;22(1):18-27.

Effect of raltegravir on ALT in subjects coinfected with HIV and hepatitis C
ScourfieldA, Waters L, Randell PA, McCormick K, Armenis K, Bower M & Nelson M
HIV Medicine 2009, 10 (Suppl1), 31

Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.
Hill A, Sawyer W, Gazzard B.
HIV Clin Trials. 2009 Jan-Feb;10(1):1-12.

Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1 infected individuals.
Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM & Goodier MR.
AIDS 2009, 23: 29-34.

Excellent immunological recovery following the intensive chemotherapy CODOX-M?IVAC, an effective therapy for HIV_assocaited Burkitt’s lymphoma.
Wilson J, Montoto S, Shaw K, Orkin C, Johnson M, Nelson M, Bower M & Cwynarski K.
HIV Medicine 2009, 10 (Suppl1), 5

Experience with ritoavir/atazanavir in HIV-positive antiretroviral naïve individuals commencing therapy
Dunning J, Myers J, Holmes P, Stuart-Buttle C, Bower M & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 18

FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease
Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M, O’Doherty M & Bower M.
Eur J Nucl Med Imaging. 2009, 36: 648-52

Gastroenteropancreatic Neuroendocrine Tumors in Patients With HIV Infection: A Trans-Atlantic Series.
Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M, Dezube BJ
Am J Med Sci. 2009 Jan;337(1):1-4.

Highly active antiretroviral therapy and the incidence of Non-AIDS defining cancers in people with HIV infection
Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H & Bower M
J Clin Oncol. 2009 Feb 20;27(6):884-90.

Highly active antiretroviral therapy and the incidence of non-AIDS defining cancers in people with HIV infection
Thomas Powles, David Robinson, Justin Stebbing, Mark Nelson, Brian Gazzard, Sundhiya Mandelia, Henrik Møller and Mark Bower
HIV Medicine 2009, 10 (Suppl1), 4

HIV testing in the UK
Gazzard B.
Lancet. 2009 Aug 1;374(9687):377

HIV opt out increases the offer and uptake of HIV tests in a GUM clinic
Price H, Sullivan AK
Int J STD AIDS. 2009 Jan;20(1):56-7.

Impact of recombinant human growth hormone on T-cell phenotype and function in vitro and in vivo during treated HIV-1 infection.
Herasimtschuk A, Nelson M, Moyle G, Bower M & Imani N
HIV Medicine 2009, 10 (Suppl1), 5.

Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors
Benn P, Sauret-Jackson V, Cartledge J, Ruff C, Sabin CA, Moyle G, Linney A, Reilly G, Edwards S.
HIV Medicine 2009;10:351-5

Interruption of antiretroviral therapy is associated with increased plasma cystatin C
Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.
AIDS. 2009 Jan 2;23(1):71-82.

Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C; on behalf of the UK Collaborative HIV Cohort (CHIC) Study
J Acquir Immune Defic Syndr. 2009 Jun 23.

Methylation reversal in high grade B-cell lymphoma cell lines identifies novel epigenetic changes conserved between immunocompetent and HIV-positive hosts and others specific to HIV-associated lymphomas.
Crook T, Syed N, Papoudou-Bai A, Stebbing J, Naresh K, Nelson M, Hatzimichael E & Bower M
HIV Medicine 2009, 10 (Suppl1), 4.

Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.
Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P, Patterson S.
J Infect Dis. 2009 Jun 15;199(12):1862-71.

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.
Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor J, Waters L, Asboe D, Gazzard B, Pozniak A.
J Acquir Immune Defic Syndr. 2009 Jul 17

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents
Coyne KM, Pozniak AL, Lamorde M, Boffito M
AIDS. 2009 Feb 20;23(4):437-46.

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L.
J Antimicrob Chemother. 2009 Jun;63(6):1233-43. Epub 2009 Mar 28

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.
AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75.

Prevention of atherosclerosis in patients living with HIV.
De Lorenzo F, Boffito M, Collot-Teixeira S, Gazzard B, McGregor JL, Shotliff K, Xiao H.
Vasc Health Risk Manag. 2009;5(1):287-300.

Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1.
Moyle G, Dejesus E, Boffito M, Wong RS, Gibney C, Badel K, Macfarland R, Calandra G, Bridger G, Becker S; X4 Antagonist Concept Trial Study Team.
Clin Infect Dis. 2009;48:798-805.

Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST; OPTIMA Team1.
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):631-9.

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration.
AIDS. 2009 Aug 24;23(13):1689-99

Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use
Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax PE
AIDS Read. 2009;19:158-60.

Sexual health of adults working in pornographic films
Coyne KM, Banks A, Heggie C, Scott CJ, Grover D, Evans C, Mandalia S, McLean KA, Cohen CE
Int J STD AIDS. 2009 Jul;20(7):508-9

Sexually transmitted diseases by Dr Lisa Marr
Barton S
AIDS Care. Vol 21. No. 4 April 2009

Steady state pharmacokinetics of plasma abacavir and intracellular carbovir triphosphate following abacavir 600mg once daily and 300g twice daily in HIV-infected subjects
Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, Lou Y, Yuen GJ, Min SS, Guerini EM.
Antimicrob Agents Chemother. 2009;53:1532-8

Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, Lou Y, Yuen GJ, Min SS, Guerini EM
Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8

Switching to raltegravir: a successful strategy in treatment-experienced patients with toxicity? 48 week data
Teague A, Scott C, Youngstein T, Bower M, Gazzard B & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 21.

The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.
HIV Med. 2009 Jan;10(1):35-43. Epub 2008 Nov 10.

The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, Boffito M, Gazzard B, Nelson M
AIDS. 2009, 23(13):1701-6.

The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals
Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J.
J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6.

The relationship between prolonged antiretroviral therapy and cryptogenic liver disease
Stebbing J, Wong N, Tan L, Scourfield A, Jiao L, Shousha S, Grover D, Bower M, Nelson M
J Acquir Immune Defic Syndr. 2009 Apr 1;50(5):554-6.

The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease.
Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M.
Ann Oncol. 2009, 20:775-9.

Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era.
Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B & Stebbing J.
J Acquir Immune Defic Syndr. 2009, 50: 113-114.

Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers.
Westrop SJ, Qazi NA, Pido-Lopez J, Nelson MR, Gazzard B, Gotch FM, Imami N.
PLoS One. 2009;4(5):e5474. Epub 2009 May 12.

Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers.
Westrop SJ, Qazi NA, Pido-Lopez J, Nelson MR, Gazzard B, Gotch FM, Imami N.
PLoS One. 2009;4(5):e5474

Use of ezetimibe during HIV infection
Stebbing J, Asghar AK, Holmes P, Bower M, Isenman HL & Nelson M. J
Antimicrob Chemother. 2009, 6: 43-52.

Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study.
J Infect Dis. 2009 Sep 1;200(5):710-4.

A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease
Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles C, Kew A, Nelson M, Kanfer E.
AIDS. 2008 Feb 19;22(4):539-40

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:54-9

A review of the clinical pharmacology of maraviroc. Introduction
Boffito M, Abel S.
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:1-4

A single centre experience with darunavir/ritonavir (DRV/r) (600mg/100mg) and optimised background regimen in clinical practice
Scott C, Jogiya R, Teague A, Bower M, Gazzard B & Nelson M
HIV Medicine 2008, 9 (Suppl 1): 14

Acquisition of HIV infection in Africans resident in London: how much and how to assess
FM Burns, R Arthur, A Johnson, J Nazroo, K Fenton; on behalf of the SONHIA collaboration group (J. Ainsworth, J. Anderson, M. Chikohora, A. Fakoya, I.Fakoya, A. Hughes, E. Jungmann, S. Manney, L. Muromba, N. Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R.
AIDS  2008; in press

Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study
Di Lorenzo G, Kreuter A, Di Trolio R, Guarini A, Romano C, Montesarchio V, Brockmeyer NH, De Placido S, Bower M, Dezube BJ
J Invest Dermatol. 2008 Jan 10

AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count
Stebbing J, Powles T, Bower M
AIDS. 2008; 22(4):551-2

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study
AIDS. 2008 Jan 30;22(3):349-56.

Azithromycin without a prescription increases access and choice for patients
Coyne KM, Barton SE, Smith NA, Cohen CE
Int. J. STD & AIDS 2008;19:870

British HIV association guidelines for HIV-associated malignancies 2008
Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N & Webb A on behalf of the AIDS malignancy subcommittee
. HIV Med 2008, 9: 336-388

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.
Gazzard BG; BHIVA Treatment Guidelines Writing Group
HIV Med. 2008 Oct;9(8):563-608.

Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments
Stebbing J, Wood C, Atkins M, Bukowski R, Litwin S, Bower M, Parsa A, Levitsky H
Cancer. 2008;112(5):955-961

CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy
Steel A, John L, Shamji MH, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.
HIV Med. 2008 Feb;9(2):118-25

Cellular immunity following chemotherapy for systemic AIDS related non Hodgkin’s lymphoma (NHL
J. Krell, M. Tuthill, V. Campbell, M. Nelson, P. Holmes, T. Powles, J. Stebbing, M. Bower
HIV Medicine 2008, 9 (Suppl 1): 24.

Clinical experience with raltegravir (MK-0518 or Isentress), with an optimised background regimen in highly treatment experienced patients
Teague A, Scott C, Youngstein T, Bower M, Gazzard B & Nelson M
HIV Medicine 2008, 9 (Suppl 1): 17.

Coding and the clinician.
Holmes P, Nelson M, Bower M, Gazzard B & Barton S.
HIV Medicine 2008, 9 (Suppl 1): 46.

Comparing the efficacy of Truvada® and Kivexa® combination therapy in HAART-naive individuals with different viral loads.
Daniels RH, Gazzard BG, Holmes P, Scourfield A, Bower M, Nelson M
Journal of the International AIDS Society 2008, 11(Suppl 1):P14 (10 November 2008)

Controversies in current treatment guidelines.
Gazzard BG.
J HIV Ther. 2008 Mar;13(1):1-3.

Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.
Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A, Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, Perez-Elias M, Castor D, Hammer S, Rinehart A, Vermeiren H, Van Craenenbroeck E, Bacheler L.
J Acquir Immune Defic Syndr. 2008 May 1;48(1):26-34.

Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group.
AIDS. 2008 Nov 12;22(17):2381-90.

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K, Hoetelmans RM.
Pharmacotherapy. 2008 Oct;28(10):1215-22.

Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy
Mihailidis C, Dunn D, Pillay D, Pozniak A
AIDS. 2008 Jan 30;22(3):427-30

Effect of PD1.3 single nucleotide polymorphism on CD4 and CD3 T cell counts in HAART-treated chronic HIV-1+ patients.
Rosignoli G, Liptrott N, Imani N, Bower M, Gotch F & Owen A
HIV Medicine 2008, 9 (Suppl 1): 8.

Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up
Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imami N.
J Immune Based Ther Vaccines. 2008; 6:7

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.
AIDS. 2008 Sep 12;22(14):1779-87.

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V
AIDS. 2008 Jan 11;22(2):275-9

Episodic sexual transmission of HIV revealed by molecular phylodynamics.
Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ.
PLoS Med. 2008 Mar 18;5(3):e50.

Etravirine use in clinical practice: 48-week data from a single centre cohort.
Scott C, Khatib N, Bower M, Gazzard BG, Nelson M.
Journal of the International AIDS Society 2008, 11(Suppl 1):P49 (10 November 2008)

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
Clumeck N, Pozniak A, Raffi F; EACS Executive Committee.
HIV Med. 2008 Feb;9(2):65-71

Ezetimibe as lipid-lowering therapy for patients receiving HAART.
Asghar AK, Bower M, Holmes P, Gazzard BG, Isenman H, Nelson M
Journal of the International AIDS Society 2008, 11(Suppl 1):P248 (10 November 2008)

Functional and phenotypic profiling of suppressive regulatory T cells in a cohort of HIV-! Infected individuals.
Burton C, Eccles-James I, Nelson M, Bower M, Gotch F & Imani N
HIV Medicine 2008, 9 (Suppl 1): 41

Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.
Macdonald DC, Nelson M, Bower M, Powles T.
World J Gastroenterol. 2008 Mar 21;14(11):1657-1663

HIV and Cardiovascular risk
Moyle G, Randell P
Clinical Medicine 2008;8:315-8.

HIV, hepatitis B and hepatitis C coinfection in Kenya
Harania RS, Karuru J, Nelson M, Stebbing J.
AIDS. 2008 Jun 19;22(10):1221-2.

HIV-associated multicentric Castleman's disease
Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ
Am J Hematol. 2008; 83(6):498-503

How can we remove barriers to HIV testing outside of GUM setting?
Barber TJ, Menon-Johanson A, Barton S
Br J Gen Pract. 2008 May: 58 (550): 365

Human immunodeficiency virus-associated renal cell carcinoma: a transatlantic case series.
Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Stebbing J, Powles T, Pantanowitz L
Clin Genitourin Cancer. 2008, 6(2):86-90

Immunological recovery in survivors following chemotherapy for AIDS related non Hodgkin's lymphoma.
Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M, Gazzard B, Powles T
Blood. 2008 Jan 2;

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group.
HIV Med. 2008 Nov;9(10):883-96

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN
J Infect Dis. 2008 Apr 15;197(8):1145-55

Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
Scott C, Grover D, Nelson M.
AIDS. 2008 May 11;22(8):989-90.

Lipid lowering effect of ezetimibe in patients with HAART-associated dyslipidaemias
Asghar A, Bower M, Gazzard B, Holmes P, Isenman H & Nelson M.
HIV Medicine 2008  9 (Suppl 1): 33.

Lipopolysaccharide-induced activation of natural killer cells from HIV-1 infected individuals
Goodier M, Gregson J, Constantinou D, Steel A, Bower M, Gazzard B & Gotch F
HIV Medicine 2008, 9 (Suppl 1): 41

Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma
Naresh KN, Rice AJ, Bower M.
Am J Surg Pathol. 2008 Jul;32(7):1006-12

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.
J Infect Dis. 2008 Apr 15;197(8):1133-44

Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.
N Engl J Med. 2008 Oct 2;359(14):1429-41

Management of HIV: still a long way to go
Pozniak A.
Br J Hosp Med (Lond). 2008 Mar;69(3):126

Missed opportunities for earlier HIV diagnosis within primary and secondary health care settings in the UK.
FM Burns, A Johnson, J Nazroo, K Fenton; on behalf of the SONHIA collaboration group (J. Ainsworth, J. Anderson, R. Arthur M. Chikohora, A. Fakoya, I.Fakoya, A. Hughes, E. Jungmann, S. Manney, L. Muromba, N. Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R.
AIDS 2008; 22:115-22.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Molina J-M, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D, for the CASTLE Study Team
The Lancet 2008: 372:646-55

Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs
Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M
J Med Virol. 2008;80:565-76

Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs
Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M.
J Med Virol. 2008;80:565-76.

Patient-delivery partner medication
Coyne, KM, Cohen CE, Smith NA, Barton SE.
Int. J. STD & AIDS 2008;19:646

Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA; on behalf of the UK Collaborative HIV Cohort (CHIC) Study Steering Committee.
HIV Med. 2008 Jan;9(1):47-56.

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.
Dickinson L, Boffito M, Khoo SH, Schutz M, Aarons LJ, Pozniak AL, Back DJ
J Antimicrob Chemother. 2008 Jul;62(1):161-7

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects
Singh K, Dickinson L, Chaikan A, Back D, Fletcher C, Pozniak A, Moyle G, Nelson M, Gazzard B, Herath D, Boffito M.
Clin Pharmacol Ther. 2008 Jun;83(6):867-72.

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G.
Antivir Ther. 2008;13(7):901-7

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G
Antivir Ther. 2008;13(7):901-7

Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs.
Sousa M, Pozniak A, Boffito M.
J Antimicrob Chemother. 2008 Nov;62(5):872-8. Epub 2008 Aug 18

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M, Miralles D, Hill A.
HIV Clin Trials. 2008 Nov-Dec;9(6):418-27.

Plasma HHV8 DNA viral load as a tumour marker for multicentric Castleman’s disease (MCD
V. Campbell, J. Krell, M. Stancliffe, M. Atkins, M. Habibi, M. Nelson, B. Gazzard, M.Bower
HIV Medicine 2008, 9 (Suppl 1): 7.

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection
Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C
AIDS Patient Care STDS 2008 May 14

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.
Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C.
AIDS Patient Care STDS 2008;22:459-71

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD
Ann Intern Med. 2008 Sep 2;149(5):289-99

Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S.
J Interferon Cytokine Res. 2008 Feb;28(2):89-100

Severe hepatotoxicity associated with darunavir
Underwood J, Scourfield A, Bell C, Harding V, Bower M & Nelson M
HIV Medicine 2008, 9 (Suppl 1): 18

Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
Byakika-Kibwika P, Lamorde M, Kalemeera F, D'Avolio A, Mauro S, Di Perri G, Ryan M, Mayanja-Kizza H, Khoo S, Back D, Boffito M, Merry C.
J Antimicrob Chemother. 2008 Nov;62(5):1113-7.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and
N Engl J Med. 2008 Oct 2;359(14):1442-55

Survival following HIV infection of a cohort followed up from seroconversion in the UK
Ewings FM, Bhaskaran K, Nock, Porter K, D, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Brettle R, Johnson M, Phillips A
AIDS. 2008 Jan 2;22(1):89-95

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.
HIV Med. 2008 Oct;9(8):667-72.

The face of HIV and AIDS: can we erase the stigma?
Kavouni A, Catalan J, Brown S, Mandalia S, Barton SE
AIDS Care. 2008 Apr; 20 (4) 485-7

The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G.
Clin Infect Dis. 2008;46:1617-23

The incidence of HIV-associated multicentric Castlemans disease
J.Krell, A. Bazeos, V. Campbell, V. Harding, T. Powles, J. Stebbing, S. Mandalia, M. Bower.
HIV Medicine 2008, 9 (Suppl 1): 7

The risks and incidence of K65R and L74V mutations and subsequent virologic responses
Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J.
Clin Infect Dis. 2008 Jan 1;46(1):96-100

The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer
Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG.
J Thorac Oncol. 2006; 1(4):324-7.

The Seroepidemiology of HTLV-1 amongst genitourinary attendees in South East London.
Turner C, Cohen CE, Sabin C, Tosswill J, Best J, Taylor G, de Ruiter A, Barlow D, Smith NA.
Journal of Clinical Virology. 2008 Oct;43(2):253-4. Epub 2008 Aug 8

The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease
Stebbing J, Ngan S, Ibrahim H, Charles P, Nelson M, Kelleher P, Naresh KN, Bower M.
Clin Exp Immunol. 2008, 154(3):399-405.

The use of antidepressants and risk of cancer in individuals infected with the human immunodeficiency virus
V. Campbell, J. Krell, A. Scourfield, S. Mandalia, M. Nelson, T. Powles, J.Stebbing, M. Bower
HIV Medicine 2008, 9 (Suppl 1): 25

Time to use text reminders in genitourinary medicine clinics
Cohen CE, Coyne KM, Mandalia S, Waters AM, Sullivan AK
Int J STD AIDS 2008 Jan; 19 (1): 12-3.

Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus
Lagos D, Vart RJ, Gratrix F, Westrop SJ, Emuss V, Wong PP, Robey R, Imami N, Bower M, Gotch F, Boshoff C
Cell Host Microbe. 2008 Nov 13;4(5):470-83

Treatment of Altered Body Composition in HIV-Associated Lipodystrophy: Comparison of Rosiglitazone, Pravastatin, and Recombinant Human Growth Hormone
Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, Moyle GJ
HIV Clin Trials 2008;9(4):253–267

Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels M, Kinghorn G, McCarron B, Pozniak A, Tang A, Walsh J, Williams I, Gazzard B.
Int J STD AIDS. 2008 May;19(5):297-304.

Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.
United Kingdom Collaborative HIV Cohort Study
 Lee KJ, Dunn D, Porter K, Bansi RG, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C.
AIDS. 2008 Oct 1;22(15):1943-50.

Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes.
Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard B, Stebbing J
Arch Intern Med. 2008, ;168(17):1926-7.

Use of antidepressants and risk of cancer in individuals infected with HIV
Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M
J Clin Oncol. 2008 May 10;26(14):2305-10

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.
AIDS. 2008 Nov 12;22(17):2279-89.

Vitamin D deficiency in the in-patients HIV population: cause or effect?
Ancock B, Bower M, Gazzard BG, Nelson M
Journal of the International AIDS Society 2008, 11(Suppl 1):P116 (10 November 2008)

When good news is bad news: psychological impact of false positive diagnosis of HIV
Bhattacharya R, Barton SE, Catalan J
AIDS Care. 2008 May; 20(5): 560-4